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c-Jun NH2-terminal protein kinase (JNK) is a mitogen-activated protein kinase (MAPK) involved in the regulation of numerous physiological
processes during development and in response to stress. Its activity is increased upon phosphorylation by the MAPK kinases, MKK4 and MKK7.
Similar to the early embryonic death of mice caused by the targeted deletion of the jnk genes, mice lacking mkk4 or mkk7 die before birth. The
inability of MKK4 and MKK7 to compensate for each other's functions in vivo is consistent with their synergistic effect in mediating JNK
activation. However, the phenotypic analysis of the mutant mouse embryos indicates that MKK4 and MKK7 have specific roles that may be due to
their selective regulation by extracellular stimuli and their distinct tissue distribution. MKK4 and MKK7 also have different biochemical
properties. For example, whereas MKK4 can activate p38 MAPK, MKK7 functions as a specific activator of JNK. Here we summarize the studies
that have shed light on the mechanism of activation of MKK4 and MKK7 and on their physiological functions.
© 2006 Elsevier B.V. All rights reserved.Keywords: MAPK; JNK; MKK4; SEK1; MKK7; JNKK; Stress1. Introduction
The c-Jun NH2-terminal protein kinases [JNKs, also called
stress activated protein kinase (SAPK)] are members of the
mitogen-activated protein kinase (MAPK) family implicated in
the regulation of a wide range of cellular functions [1]. Three
genes, jnk1, jnk2, and jnk3 encoding ten isoforms have been
identified in mammals. JNK1 and JNK2 isoforms are
ubiquitously expressed, while JNK3 is almost exclusively
found in the brain and testis. The generation of genetically
modified mice deficient in one or more of the jnk genes has
greatly facilitated the functional analysis of the role of JNKs in
vivo [1]. In particular, these studies have highlighted the
importance of JNK-mediated apoptosis during the development
of the central nervous system (CNS) and in response to brain
injury [2,3]. However, apoptosis does not represent the only
functional consequence of JNK activation. For example, JNKs
appear to contribute to cell survival, cell proliferation and the
immune response [1].
Analogous to other MAPKs, JNKs are activated via the
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multiple MAP kinase kinase kinases (MKKKs) (Fig. 1) [4]. The
MKKKs phosphorylate and activate MKK4 and MKK7 which,
in turn, activate JNKs by dual phosphorylation on Thr and Tyr
residues within a Thr–Pro–Tyr motif in protein kinase
subdomain VIII. While MKK7 is a specific activator of JNKs,
MKK4 can also phosphorylate the Thr–Gly–Tyr motif of p38
MAPKs [1]. Like JNKs, p38 MAPKs are activated in
mammalian cells by various stress stimuli and pro-inflamma-
tory cytokines [5]. The specific transmission of signals from the
upstream kinases to the MAPKs is ensured by interactions
between the components of the cascade either directly or via
scaffold proteins (Fig. 1) [6,7]. Both mechanisms may operate
in parallel to allow differential responses of the same MAPK
signaling pathway to different stimuli.
The identification of physiologically relevant downstream
targets has shed light on the biochemical mechanisms that
account for the effects of JNKs. These targets include
transcription factors [8], microtubule-associated proteins
(MAPs) [9,10] and members of the Bcl-2 family [11–15]
(Fig. 1). Further understanding of the physiological functions of
JNK has come from the targeted deletion of its activators,
MKK4 and MKK7, which has allowed the functional effect of
loss of JNK activation to be examined as opposed to loss of
Fig. 1. Signal transduction mediated via MKK4 and MKK7. MKK4 and MKK7 activate JNKs by dual phosphorylation on Thr and Tyr residues [1]. MKK7 is a
specific activator of JNK, while MKK4 can also stimulate p38 MAPK activity [17,18,25–30]. Multiple MKKKs phosphorylate and activate MKK4 and MKK7 [1,4].
The specific transmission of stress signals from upstream kinases to JNK is ensured by interactions between the components of the cascade either directly or via
scaffold proteins [6,7]. Downstream targets of JNKs include numerous transcription factors [8], MAPs [9,10], and pro-apoptotic Bcl-2 family members [11–15].
Transcription factors and protein kinases such as MAPK-activated protein kinase 2 (MAPKAPK2 or MK2) and MAPK-interacting kinase 1 (MNK1) downstream of
the p38 MAPKs constitute additional mediators of MKK4 signaling [5].
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MKK4 and MKK7 highlighting the phenotypic similarities and
differences between mice with defects in MKK4 and MKK7
signaling and discuss unresolved questions regarding the
function of MKK4 and MKK7 in vivo.
2. Biochemical characterization of MKK4 and MKK7
2.1. Identification and cloning
XMEK2 was originally identified in screens for novel MKK
family members in Xenopus laevis [16]. The mouse and human
homologues were subsequently cloned and named SEK1 (for
SAPK or extracellular-signal-regulated protein kinase (ERK)
kinase-1) and MKK4 or JNKK1 (for JNK kinase 1),
respectively [17–19]. Gene analysis revealed that the mouse
gene located on chromosome 11 is encoded by 11 exons.
Evidence for the existence of an additional JNK activator was
first provided by biochemical studies [20,21]. The ability of UV
radiation and osmotic shock to activate JNK in murine
embryonic stem (ES) cells lacking MKK4 confirmed that
MKK4 was not the sole activator of JNK [22–24].
MKK7, also called SEK2 or JNKK2, was cloned by several
laboratories [25–30]. It is most similar to the Drosophila JNKactivator hemipterous (hep) and mammalian MKK4, sharing
70% and 55% amino acid identity within their respective kinase
domains. Complementation experiment demonstrated that
MKK7 could substitute for hep at certain stages during Dro-
sophila development [27]. The gene, located on mouse
chromosome 8, encodes 14 exons that can be alternatively
spliced to generate a group of protein kinases with three
different N-termini (α, β, and γ isoforms) and two different
C-termini (1 and 2 isoforms) [31]. With predicted molecular
mass of between 38 and 52 kDa, the full-length proteins contain
between 345 and 467 amino acids. However, the physiological
relevance of different MKK7 isoforms remains to be proven.
Comparison of the activities of the MKK7 isoforms towards
JNK demonstrated that MKK7α, which lacks the NH2-terminal
extension, exhibits a lower basal activity than MKK7β and γ
isoforms [31]. This could be explained by the ability of the β
and γ isoforms to bind JNK via three D domains present in their
N-terminus (Fig. 2) [32]. D domains are characterized by a
cluster of positively charged amino acids surrounded by
hydrophobic amino acids [6]. They recognise amino acid
sequences in the C-termini of the MAPKs identified as the
common docking (CD) domain [6]. Similar to MKK7, MKK4
interacts with JNK but via a single D domain present in its
N-terminus (Fig. 2) [33].
Fig. 2. Schematic illustration of functional domains identified in MKK4 and MKK7. MAPK and MAPKKK docking domains referred as D and DVD sites in MKKs
permit the formation of stable complexes between the components of the MAPK signaling pathway [6,49]. These interactions contribute to accurate and efficient
enzyme–substrate recognition and are essential for the specific transmission of signals from upstream kinases to the MAPKs. The D sites in MKK4 and MKK7 consist
of a cluster of two to three basic residues, followed by a short spacer of 1–2 residues, and a hydrophobic-X-hydrophobic sub-motif [32,33]. Unlike MKK4, MKK7
contains three weak D-sites that interact in a partially additive, partially synergistic manner to create high affinity JNK-docking platform [32]. The specific MAPKKK-
MKKs interaction via the DVD site facilitates the phosphorylation of MKK4 andMKK7 at Ser and Thr residues within the S–X–A–K–Tmotif, by increasing the local
concentration of the activating MAPKKK and altering the structure of the MKKs [49]. Consensus-matching residues in the putative D and DVD sites of MKK4 and
MKK7 are in boldface.
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Although MKK4 and MKK7 are ubiquitously expressed in
all organs in the adult mouse, their pattern of expression
during fetal development is notably different which may
underscore their distinct functions during embryogenesis. For
example, the murine mkk4 transcript is confined to the CNS,
including the spinal cord, up until embryonic day 10 (E10)
[34]. At E12, the mRNA becomes highly expressed in the
developing liver when the organ undergoes active differentia-
tion, remains elevated during the period the liver increases its
size (E16), and declines rapidly thereafter [34]. Unlike in the
liver, the expression of mkk4 in the CNS gradually increases
during late embryogenesis with the highest levels at E18 and
after birth [34]. Similar to the early postnatal periods, the
adult displays the highest levels of mkk4 in the cerebral
cortex, the hypothalamus, the hippocampus, and the cere-
bellum [34,35]. Overall, the level of expression of mkk7
mRNA is lower than that of mkk4 particularly in the liver
[36]. During embryogenesis, the mkk7 transcript is found
mainly in epithelial tissues such as skin, lung, epithelium andepithelial layers lining the olfactory cavity and developing
teeth [28,36].
No marked difference was observed in the sub-cellular
localization of MKK4 and MKK7 in mitotic cells [31].
However, the MKKs display a distinct distribution in neurons
where MKK4 is present in both the cell body and the processes
(dentrites and axons), while MKK7 is almost exclusively
detected in the nucleus [37]. Together with JNK, MKK4
translocates to the cell body upon stimulation [37]. Conse-
quently, while both MKK4 and MKK7 can stimulate JNK in the
nuclear fraction, MKK4 is likely to be critical to maintain the
high basal activity of JNK in neurites. By enabling JNK to
phosphorylate cytosolic targets such as MAPs, MKK4 may
have a prominent role in mediating the effect of JNK on
dendritic outgrowth and the establishment of functional neural
circuits in the brain [9,10,38].
2.3. Catalytic activity
The catalytic domains of MKK4 and MKK7 exhibit around
40% sequence similarity with the other members of the MKK
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small, mainly β-stranded, N-terminal lobe and a larger helical
C-terminal lobe [39]. The ATP binding site is located in the cleft
formed between the two lobes and is surrounded by conserved
residues. The main difference between the MKK4 and MKK7
catalytic activities resides in the ability of MKK4 to activate
both JNKs and p38 MAPKs, while MKK7 is a specific activator
of JNKs [17,18,25–30] (Fig. 1). The physiological evidence for
a role of MKK4 in activating the p38 MAPK cascade was
provided in mouse embryonic fibroblasts (MEFs) lacking both
MKK3 and MKK6 [40]. Decreased expression of MKK4 by
siRNA strongly suppressed UV-induced p38 MAPK activation
in mkk3−/−mkk6−/− but not in wild type cells. In contrast,
MKK4 does not contribute to mediating p38 activation in
response to tumour necrosis factor α (TNFα) [40].
In addition, the JNK activators display different substrate
specificities towards the Thr–Pro–Tyr motif, with MKK4 and
MKK7 preferentially phosphorylating JNK isoforms on the
tyrosine and the threonine residue, respectively [17,41–45].
This observation led to the idea of synergistic activation of
JNKs by MKK4 and MKK7 [41–43]. Unlike the other MAPK
subfamilies, the mono-phosphorylation of JNKs on Thr residue
is sufficient to increase JNK activity, suggesting that MKK7
may be a more robust activator of JNKs than MKK4 [44].
Consistently, activation of JNKs in response to TNFα and IL-1
was almost completely lost in the mkk7−/− cells, but reduced by
50% in mkk4−/− cells [44]. These data indicated that while
MKK4 is required for optimal JNK activation, MKK7 is
essential for the stimulation of JNK activity by pro-inflamma-
tory cytokines. Biochemical studies corroborated this model by
showing that TNFα and IL-1 mainly activate MKK7
[30,46,47]. In contrast, environmental stresses activate both
MKK4 and MKK7 [30,46]. A significant defect in JNK
activation caused by UV radiation, anisomycin, heat and
osmotic shock was observed in the mkk4−/− and mkk7−/− ES
cells and MEFs, supporting the evidence that both MKK4 and
MKK7 contribute to the activation of JNKs in response to stress
signals [22–24,44,48].
3. Mechanism of activation
3.1. Upstream kinases
MKK4 and MKK7 activity is increased following phosphor-
ylation at Ser and Thr residues within a Ser–Xaa–Ala–Lys–Thr
(S–X–A–K–T) motif in the activation loop by multiple
MKKKs, including MEKK1–4, the protein kinases of the
mixed lineage kinase (MLK) family, apoptosis signal-regulated
kinase 1 (ASK1), and TGFβ-activated kinase 1 (TAK1) (Fig. 1)
[4]. Similar to MKK3 and MKK6, the amino acid following the
Ser residue corresponds to a hydrophobic residue (Ile) in
MKK4, while a basic amino acid (Lys) is found in MKK7β.
This difference may, in part, explain the distinct specificity of
certain MKKKs for the JNK activators. For example, while
MEKK1 can phosphorylate both MKK4 and MKK7, MEKK4
is a specific activator of MKK4 [49]. This is consistent with the
ability of MEKK1 to bind to both MKK4 and MKK7 whileMEKK4 specifically interacts with MKK4 [49]. Specific
MKKK–MKK interactions are mediated via a docking domain
of about 24 amino acids located in the C-termini of MKK4 and
MKK7, and named the “domain for versatile docking” (DVD)
(Fig. 2). In addition to contributing to the specific activation of
MKK4 and MKK7 by upstream kinases, binding via the DVD
site may affect the structure of the MKK4 and MKK7 activation
loops so that the serine and threonine residues of the S–X–
A–K–T motif become accessible for phosphorylation [49].
In addition to the DVD site, the N-terminus of MKK4 that is
required for binding to JNKs contributes to the formation of a
stable MEKK1–MKK4 complex [50]. Since no ternary
complex could be detected and the activation of MKK4
prevented its binding to MEKK1, the sequential formation of
bipartite interactions between MEKK1 and MKK4, and MKK4
and JNK has been proposed [50]. A change in conformation
caused by protein phosphorylation enables MKK4 to dissociate
from MEKK1 and to become free to interact with its substrate
JNK. In contrast, a trimeric molecular complex consisting of
MEKK2, MKK7, and JNK was shown to be responsible for
increasing JNK activity [51]. In this scenario, the interaction
between any two of these three kinases was strengthened by the
presence of the third. Upon activation, MKK7 and JNK
dissociate from MEKK2, allowing MEKK2 to bind to and
activate more substrates and hence amplify the upstream signal
[51].
3.2. Adaptor/scaffold proteins
In addition to direct physical interactions between JNK and
its upstream protein kinases, adaptor/scaffold proteins that
assemble the different components of the cascade have been
proposed to facilitate activation and regulate sub-cellular
localization (Fig. 1) [7]. The JNK interacting proteins (JIP1,
JIP2, JIP3, JIP4) are the best-characterized JNK pathway
scaffold proteins [52]. JIP3 and JIP4 are highly related to each
other but their sequences are distinct from those of JIP1 and
JIP2, apart from within the JNK binding domain. JIP proteins
play important roles in brain development, neuronal trafficking,
apoptosis, β-cell function and insulin responses by tethering
distinct JNK signaling modules [52]. For example, JIP1–3 bind
to JNK, MKK7 and members of the MLK family, while a
spliced variant of JIP3, JSAP1, scaffolds an MEKK1–MKK4–
JNK module [52]. JIP4 binds to JNK and ASK1 but not to
MKKs or MLKs and does not seem to enhance JNK activation
while the JIP4 variants, JLP and SPAG9 do form functional
JNK signaling complexes [52].
Originally identified by a yeast two-hybrid screen as a
binding partner of Rac1, the multi-domain protein POSH
(plenty of SH3s) was subsequently found to form complexes
with the protein kinases of the MLK family, as well as MKK4,
MKK7, and JNK [53]. Its ability to induce neuronal death has
led to the hypothesis that POSH is a scaffold protein that
participates to Rac1-induced neuronal apoptosis via the JNK
signaling pathway. The physiological function of POSH in the
brain has been shown in Xenopus where it was found to be
essential for the anterior neural development during early
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Drosophila have provided genetic evidence for a role of POSH
in the immune system [55].
4. Biological functions
4.1. Insights from animal models
4.1.1. The liver
The early embryonic death caused by the targeted deletion of
the mkk4 or mkk7 genes in mice provided the first genetic
evidence that MKK4 and MKK7 have non redundant functions
in vivo [22–24,56,57]. The mkk4−/− and mkk7−/− embryos die
between E11.5 to E13.5 of anemia associated with abnormal
hepatogenesis [24,36,57,58]. In addition, the mkk4−/− fetuses
exhibited a severe hemorrhage in the region of the liver at E12.5
associated with increased apoptosis [24,36,58]. The disorga-
nized architecture of the mkk4 and mkk7 null mutant livers
correlated with a defect in hepatoblast proliferation at around
E11.5 [57,58]. Similar to c-junAA fibroblasts carrying a mutant
of c-Jun in which both JNK phosphorylation sites have been
replaced by Ala residues, primary mkk7−/− hepatoblasts
displayed down-regulated expression of the G2/M cell cycle
kinase Cdc2 [57]. The promoter region of the cdc2 gene
contains a number of AP-1 sites to which c-Jun can bind [57].
Consequently, Cdc2 constitutes a potential downstream target
by which the MKK7-JNK-c-Jun signaling pathway regulates
cell proliferation. The molecular mechanisms that account for
the effects of MKK4 remain largely uncharacterized
4.1.2. The immune system
The functional importance of MKK4 during the develop-
ment of lymphoid cells and in the immune response has been
studied in mkk4−/− chimeras using recombination-activating
gene (RAG)2 blastocyst complementation. One group found
that the development of both B and T cell lineages was impaired
in the absence of MKK4 [22,59]. The chimeric mice had smaller
thymi with reduced numbers of CD4+CD8+ double-positive
(DP) immature thymocytes. Furthermore, the transition from
pro-B to pre-B cells in the bone marrow was blocked. Peripheral
B cells could be activated normally, while peripheral T cells
exhibited decreased proliferation and IL-2 production following
activation [59]. In addition, DP thymocytes and peripheral
T cells lacking MKK4 expression were significantly more
susceptible than wild type cells to cell death triggered by CD95
or CD3 cross-linking [22,60].
A second study contradicted these data by finding no
evidence that MKK4 was required for the development of T and
B lymphocytes or for protecting thymocytes from cell death
[61]. Instead, the mkk4−/−rag2−/− chimeric mice exhibited
grossly visible lymphadenopathy at the age of 2–6 months that
did not appear to result from tumour formation [61]. These
discrepancies between studies could be due firstly to different
homozygous mkk4−/− ES clones being used, and secondly to
alterations in ES cells that affect their ability to reconstitute B
and T lineage cell populations in the context of RAG-deficient
blastocyst complementation. The generation of mice withspecific inactivation of MKK4 in T and B lymphocytes should
help to resolve this issue.
Similar studies based on the RAG-deficient blastocyst
complementation approach indicated that MKK7 was not
required for thymocyte development [56,62]. Instead, the loss
of MKK7 caused an enlarged thymus and hyper-proliferation of
hematopoietic cells in response to antigen or growth factor
receptor stimulation. Enhanced proliferation of the non-
lymphoid bone marrow mast cell lines lacking MKK7
correlated with up-regulation of cyclin D1 together with loss
of expression of JunB and the cell cycle inhibitor p16INK4a [62].
JNK activation was completely abolished in mkk7−/− mast cell
lines, despite up-regulation of MKK4, suggesting that MKK7 is
essential for JNK activation in mast cells. Like jnk1−/−jnk2−/−
T cells, activated mkk7−/− lymphocytes were responsive to
T cell receptor (TCR) stimulation in the presence or absence of
CD28 [56]. The large amounts of all the T helper cell (Th) 2
cytokines, such as IL-4, produced by the mkk7−/− T cells
suggests that MKK7 may be required for polarized differentia-
tion of Th cells into Th1 lineage [56]. Unlike MKK4 deficiency,
thymocytes and mast cell lines lacking MKK7 were equally
susceptible to cell death as wild type cells [62].
4.2. Role of MKK4 and MKK7 in heart disease
Cardiac hypertrophy is the key step associated with the onset
of heart failure. It involves the alteration of myocyte shape that
results in wall thickening, followed by chamber dilation and
myocardiac dysfunction. This process is initially compensatory
to normalize systolic wall stress caused by an increased
workload, the prolongation of which leads to congestive
arrhythmia, heart failure and sudden death. Both JNK activation
and hypertrophy in response to pressure overload were blocked
following the expression of a dominant-negative mutant form of
MKK4 (MKK4-KR) in the rat heart [63]. These results are
consistent with the defect in hypertrophy and contractile
dysfunction induced by over-expression of Gαq in mice lacking
MEKK1 expression [64]. However, the same mekk1−/− mouse
model subjected to pressure overload by aortic constriction
showed no effects on the hypertrophic response [65]. Instead,
pressure overload caused elevated levels of apoptosis and
inflammatory lesions in these mice.
The role of MKK7 in cardiac disease was assessed by using a
mouse model over-expressing a dominant active mutant form of
MKK7 (MKK7D) in ventricular myocytes [66]. MKK7D
expression led to significant JNK activation. Despite lacking
ventricular hypertrophy, MKK7D mice exhibited profound
diastolic dysfunction and premature death with signs of
congestive heart failure [66]. MKK7D mutant hearts were
substantially less compliant. The stiffness was correlated with
interstitial fibronectin accumulation possibly induced by
elevated expression levels of TGFâ family members [66]. A
significant slowing of ventricular electrical conduction in the
hearts displaying high levels of JNK activity was the result of a
loss of connexin 43 expression and gap junctions, a common
hallmark of the failing heart that contributes to arrythmogenesis
[66]. Gene array analysis revealed that activation of the MKK7-
Fig. 3. Model of the regulation of neuronal apoptosis by MKK4 and MKK7.
JNK controls mitochondrial permeability via post-translational modifications of
the pro-apoptotic Bcl-2 family members Bid, Bax and Bim [11–15]. However,
in contrast to other cell types, the redistribution of cytochrome c is not the only
regulated step during neuronal apoptosis. The additional changes that make a
neuron competent to receive the cytochrome c signal may involve JNK-
dependent regulation of new gene expression [1]. Based on their subcellular
localization [37], it is possible that the “competence-to-die” is developed
following the nuclear activation of JNK by both MKK4 and MKK7 and the
subsequent increase in AP-1 activity, while MKK4-dependent activation of JNK
in the cytoplasm leads to cytochrome c release.
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angiogenesis, potassium regulation and extracellular matrix
[67].
4.3. Role of MKK4 in cancer
The inactivation of tumour suppressor genes is a key feature
of cancer formation and progression. Tumour suppressor genes
are inactivated through loss of heterozygosity (LOH) or
following homozygous deletion. In humans, mkk4 is located
at chromosome 17p11.2, proximal to the p53 tumour suppressor
gene [68]. It has been hypothesized to be a tumour suppressor
gene, since loss-of-function mutations in mkk4 are found at a
fairly consistent rate (∼5%) in primary cancers of the pancreas,
bile ducts, breast, colon, lung and testis [68,69]. Genetic
alterations of the mkk4 gene include homozygous deletions or
intragenic nonsense and missense mutations. Coexistent muta-
tions of other tumour suppressor genes, such as p53, BRCA and
p16, in mkk4-deficient tumours suggest that mkk4 may
participate in a distinctive tumour suppressive signaling path-
way [68,69]. Nearly all mutated mkk4 sequences code for
truncated or altered proteins that do not exhibit normal kinase
activity [68]. Impaired expression of MKK4 in prostate and
ovarian tumours appeared to be linked with more advanced
stages of cancer progression [70,71]. Consistently, mouse
experimental models have demonstrated that over-expression
of MKK4 did not affect the proliferation of cancer cells but
suppressed cancer metastasis and prolonged animal survival
[71–74]. A possible explanation is that the loss of MKK4
results in resistance to apoptosis induced by extracellular stress
signals, thus enhancing metastatic colonization.
On the contrary, other studies have shown that MKK4 is
pro-oncogenic [75,76]. The lack of MKK4 resulted in a
cellular susceptibility to stress-induced apoptosis and sup-
pressed growth, while MKK4 over-expression stimulated
proliferation and invasion of breast and pancreatic cancer
cells [75]. Consistently, injection of pancreatic cancer cell
lines with disrupted MKK4 alleles produced a less
aggressive phenotype with fewer metastases, instead of a
growth advantage [76]. These contradictory findings indicate
that MKK4, like JNK, may be a tumour suppressor or
accelerator depending on the environmental context [77–79].
For example, human tumours associated with the natural
loss of MKK4 may have been selected for mutations that
confer growth advantage in a competitive environment of
cells [68–73].
5. Concluding remarks
The early embryonic lethality caused by the targeted deletion
of the mkk4 or the mkk7 genes overturned the idea that MKK4
and MKK7 were functionally redundant for JNK activation
[22–24,56,57]. The inability of the MKKs to compensate each
other in vivo can be partly explained by their distinct specificity
for Tyr and Thr residues in vitro [17,41–45]. But, the
synergistic activation of JNK by MKK4 and MKK7 is
inconsistent with their distinct tissue distribution in the embryoand their different sub-cellular localization in certain cell types
[28,34–37]. Thus, it is possible that in vivo other proteins, such
as scaffold proteins, may alter the properties of the MKKs
resulting in the gain of dual-specificity kinase activity.
Investigation of the endogenous states of phosphorylation of
JNK will be critical to understand the molecular mechanism of
the synergistic activation of JNK in various cell types in
response to different stimuli.
Further evidence that MKK4 and MKK7 have distinct
functions is underscored by differences in the phenotypic
abnormalities displayed by the mkk4−/− and mkk7−/− embryos.
The functional diversification of the JNK activators may be
based on selective regulation by extracellular stimuli and the
ability to activate JNK in different cellular compartments. For
example, in neurons MKK4 is present in both the cell body and
the processes, while MKK7 is almost exclusively detected in the
nucleus [37]. The co-localization of MKK4 with the high basal
activity of JNK in processes suggests that MKK4 may play a
critical role in establishing the dendritic architecture during
brain development through the activation of JNK [9,10,38]. In
response to stress, MKK4 translocates to the cell body where,
together with MKK7, they activate JNK and promote apopto-
sis via transcription-independent and -dependent mechanisms
(Fig. 3). Alternatively, MKK4 and MKK7 may have other
cellular roles in addition to activating JNK. This is exemplified
by the ability of MKK4 to activate p38 MAPKs [17,18,40].
One study has reported the activation of the p38 MAPK δ
isoform by MKK7, but the physiological relevance of this
result remains to be determined [80].
Although gene targeting studies have provided useful
information to individually dissect the role of MKK4 and
MKK7 in vivo, conflicting findings have been published. For
example, the requirement of MKK4 for cell survival in liver
during development [24,36,58] and the immune response
[22,60] seems inconsistent with increased resistance of the
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larly, MKK7 negatively regulates growth factor and antigen
receptor driven proliferation in hematopoietic cells [62],
while mkk7−/− hepatoblasts and fibroblasts display a
proliferation defect [44,57]. These apparent discrepancies
underscore the versatility of MKK4 and MKK7 function and
highlight the need for novel mouse models with specific
defects in MKK4 and MKK7 in particular tissues and
organs. It will be particularly interesting to use these mice
and test the role of MKK4 and MKK7 in brain, heart, liver
and skin during development, and in response to stresses that
mimic diseases. The identification of tissue-specific down-
stream targets of MKK4 and MKK7 will be essential to increase
our understanding of how JNK mediates its physiological
effects.
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